Page last updated: 2024-10-20

pteridines and Lymphoma, Non-Hodgkin

pteridines has been researched along with Lymphoma, Non-Hodgkin in 3 studies

Lymphoma, Non-Hodgkin: Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (33.33)18.2507
2000's0 (0.00)29.6817
2010's2 (66.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Nguyen, T1
Parker, R1
Hawkins, E1
Holkova, B1
Yazbeck, V1
Kolluri, A1
Kmieciak, M1
Rahmani, M1
Grant, S1
Vose, JM1
Friedberg, JW1
Waller, EK1
Cheson, BD1
Juvvigunta, V1
Fritsch, H1
Petit, C1
Munzert, G1
Younes, A1
Dhondt, JL1
Millot, F1
Hayte, JM1
Mazingue, F1
Farriaux, JP1

Trials

1 trial available for pteridines and Lymphoma, Non-Hodgkin

ArticleYear
The Plk1 inhibitor BI 2536 in patients with refractory or relapsed non-Hodgkin lymphoma: a phase I, open-label, single dose-escalation study.
    Leukemia & lymphoma, 2013, Volume: 54, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Cell Cycle Proteins; Female; Humans; Lymphoma, Non-Hodgkin; Male; Mi

2013

Other Studies

2 other studies available for pteridines and Lymphoma, Non-Hodgkin

ArticleYear
Synergistic interactions between PLK1 and HDAC inhibitors in non-Hodgkin's lymphoma cells occur in vitro and in vivo and proceed through multiple mechanisms.
    Oncotarget, 2017, May-09, Volume: 8, Issue:19

    Topics: Animals; Caspases; Cell Cycle Checkpoints; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation

2017
2,4-diamino-7-hydroxy-pteridines in biological fluids of patients on high-dose methotrexate.
    Clinica chimica acta; international journal of clinical chemistry, 1993, Nov-15, Volume: 220, Issue:2

    Topics: Adolescent; Adult; Child; Child, Preschool; Dose-Response Relationship, Drug; Female; Humans; Infant

1993